Overview

S-Equol in Alzheimer's Disease (SEAD) Trial

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if S-equol could benefit persons with Alzheimer's Disease (AD).
Phase:
Phase 1
Details
Lead Sponsor:
Russell Swerdlow, MD
Collaborator:
Ausio Pharmaceuticals, LLC
Treatments:
Equol